Piperine as an inhibitor of Rv1258c, a putative multidrug efflux pump of Mycobacterium tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 8, 2010, Pages 1694-1701

  Sharma, Sandeep ^a   Kumar, Manoj ^a   Sharma, Sujata ^a   Nargotra, Amit ^a   Koul, Surrinder ^a   Khan, Inshad Ali ^a  

^a CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

Docking; Efflux pump inhibitors; Kill kinetics; MPC; PAE; Rifampicin

Indexed keywords

BACTERIAL PROTEIN; CARRIER PROTEIN; ETHIDIUM BROMIDE; PIPERINE; PROTEIN RV1258C; RIFAMPICIN; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; ABC TRANSPORTER; ALKALOID; AMIDE; ENZYME INHIBITOR; PIPERIDINE DERIVATIVE; RV1258C PROTEIN, MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERICIDAL ACTIVITY; COMPUTER MODEL; DRUG BINDING; DRUG POTENTIATION; GENE MUTATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; POSTANTIBIOTIC EFFECT; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST; POLYMERASE CHAIN REACTION; PROTEIN TERTIARY STRUCTURE;

ALKALOIDS; ANTITUBERCULAR AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BACTERIAL PROTEINS; BENZODIOXOLES; DRUG SYNERGISM; ENZYME INHIBITORS; GENE EXPRESSION PROFILING; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PIPERIDINES; POLYMERASE CHAIN REACTION; POLYUNSATURATED ALKAMIDES; PROTEIN STRUCTURE, TERTIARY; RIFAMPIN;

EID: 77954710540     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq186     Document Type: Article

References (38)

1. Boogaard J, Kibiki GS, Kisanga ER et al. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 2009; 53: 849-62.
2. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996; 64: 2062-9.
3. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001; 40: 327-41.
4. Maggi N, Pasqualucci CR, Ballotta R et al. Rifampicin: a new orally active rifamycin. Chemotherapy 1996; 11: 285-92.
5. Ohno H, Koga H, Kohno S et al. Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob Agents Chemother 1996; 40: 1053-6.
6. Lomovskaya O, Lee A, Hoshino K et al. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 43: 1340-6.
7. Van Bambeke F, Balzi E, Tulkens PM. Antibiotic efflux pumps. Biochem Pharmacol 2000; 60: 457-70.
8. Danilchanka O, Mailaender C, Niederweis M. Identification of a novel multidrug efflux pump of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2008; 52: 2503-11.
9. Louw GE, Warren RM, Gay van Pittius NC et al. A balancing act: efflux/ influx in mycobacterial drug resistance. Antimicrob Agents Chemother 2009; 53: 3181-9.
10. Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44.
11. Amaral L, Martins M, Viveiros M. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that effect the activity of efflux pumps. J Antimicrob Chemother 2007; 59: 1237-46.
12. Ainsa JA, Blokpoel MC, Otal I et al. Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis. J Bacteriol 1998; 180: 5836-43.
13. Siddiqi N, Das R, Pathak N et al. Mycobacterium tuberculosis isolate with a distinct genomic identity over-expresses a tap-like efflux pump. Infection 2004; 32: 109-11.
14. De Rossi E, Ainsa JA, Riccardi G. Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol Rev 2006; 30: 36-52.
15. Jiang X, Zhang W, Zhang Y et al. Assessment of efflux pump gene expression in a clinical isolate Mycobacterium tuberculosis by real-time reverse transcription PCR. Microb Drug Resist 2008; 14: 7-11.
16. Atal CK, Zutshi U, Rao PG. Scientific evidence on the role of ayurvedic herbals on bioavailability of drugs. J Ethnopharmacol 1981; 4: 229-32.
17. Atal CK, Dubey RK, Singh J. Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism. J Pharmacol Exp Ther 232: 258-62.
18. Singh J, Dubey RK, Atal CK. Piperine-mediated inhibition of glucuronidation activity in isolated epithelial cells of the guinea-pig small intestine: evidence that piperine lowers the endogenous UDP-glucuronic acid content. J Pharmacol Exp Ther 1986; 236: 488-93.
19. Sunila ES, Kuttan G. Immunomodulatory and antitumor activity of Piper longum Linn. and piperine. J Ethnopharmacol 2004; 90: 339-46.
20. Khan IA, Mirza ZM, Kumar A et al. Piperine, a phytochemical potentiator of ciprofloxacin against Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 810-2.
21. Kumar A, Khan IA, Koul S et al Novel structural analogues of piperine as inhibitors of the NorA efflux pump of Staphylococcus aureus. J Antimicrob Chemother 2008; 16: 1270-6.
22. Eliopoulos GM, Wennersten CB. Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycinresistant enterococci. Antimicrob Agents Chemother 2002; 46: 1319-24.
23. Alvireaz-Freits EJ, Carter JL, Cynamon MH. In vitro and in vivo activity of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46: 1022-5.
24. Kumar M, Khan IA, Verma V et al. Rapid, inexpensive MIC determination of Mycobacterium tuberculosis isolates by using microplate nitrate reductase assay. Diag Microbiol Infect Dis 2005; 53: 121-4.
25. Jayaram R, Gaonkar S, Kaur P et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003; 47: 2118-24.
26. Dong Y, Zhao X, Kreiswirth BN et al. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000; 44: 2581-4.
27. Chiu CY, Au-Yeang C, Yew WW et al. Postantibiotic effects of antituberculosis agents alone and in combination. Antimicrob Agents Chemother 2001; 45: 3631-4.
28. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000; 132: 365-86.
29. http://www.sbg.bio.ic.ac.uk/phyre/ (19 April 2010, date last accessed).
30. Nargotra A, Sharma S, Datt M et al. Structure characterization of NorA, a multidrug resistant efflux pump of Staphylococcus aureus using in silico approaches. Abstracts of the Sixth International Conferences on Bioinformatics, Hong Kong, 2007. Abstract 33, p. 71. Hong Kong University of Science and Technology, Hong Kong.
31. http://www.schrodinger.com (19 April 2010, date last accessed).
32. Sabatini S, Katz GW, Rossolini GM et al. From phenothiazone to 3-phenyl-1,4-benzothiazine derivatives as inhibitors of the Staphylococcus aureus NorA multidrug efflux pump. J Med Chem 2008; 51: 4321-30.
33. http://nihserver.mbi.ucla.edu/SAVES (19 April 2010, last date accessed).
34. Gumbo T, Louie A, Deziel MR et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007; 51: 3781-8.
35. Mailaender C, Reiling N, Engelhardt H et al. MspA porin promotes growth and increases antibiotic susceptibility of both Mycobacterium bovis BCG and Mycobacterium tuberculosis. Microbiology 2004; 150: 853-64.
36. Brenwald NP, Gill MJ, Wise R. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998; 42: 2032-5.
37. Jones HE, Brenwald NP, Owen KA et al. A multidrug efflux phenotype mutant of Streptococcus pyogenes. J Antimicrob Chemother 2003; 51: 707-10.
38. Valle MB, Leon AP, Huertero CA et al. rpoB gene mutations in rifampin-resistant Mycobacterium tuberculosis identified by polymerase chain reaction single-stranded conformational polymorphism. Emerg Infect Dis 2001; 7: 1010-3.